<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1406222190
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RUCORON 50MG\5ML SOLUTION FOR IV BOLUS OR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROCURONIUM BROMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        182.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Farmaceutica" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Farmaceutica
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M03AC09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rucoron is one of a group of drugs called muscle relaxants.</p><p>Muscle relaxants are used during an operation as part of a general anaesthetic. When you have an operation your muscles must be completely relaxed. This makes it easier for the surgeon to perform the operation.</p><p>Normally, your nerves send messages called impulses to your muscles. Rucoron acts by blocking these impulses so that your muscles relax. Because your breathing muscles also relax, you will need help to breathe (artificial ventilation) during and after your operation until you can breathe on your own again.</p><p>During the operation your anaesthetist will keep a check on the effect of the muscle relaxant, and if necessary will give you some more. At the end of surgery, the effects of the drug are allowed to wear off and you will start breathing on your own. Sometimes the anaesthetist will give you another drug to help speed this up.</p><p>Rucoron can also be used in Intensive Care Units to keep your muscles relaxed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not receive Rucoron</strong></p><ul><li>If you are allergic (hypersensitive) to rocuronium, the bromide ion or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Tell your anaesthetist if this applies to you.</p><p><strong>Warnings and precautions</strong><br /><em>Talk to your anaesthetist before you receive this medicine:</em></p><ul><li>If you are allergic to muscle relaxants</li><li>If you have had kidney, heart, liver or gall bladder disease</li><li>If you have had diseases affecting nerves and muscles</li><li>If you have fluid retention (oedema)</li></ul><p>Tell your anaesthetist if any of these applies to you.</p><ul><li>If you have a history of malignant hyperthermia (sudden fever with rapid heartbeat, rapid breathing and stiffness, pain and/or weakness in your muscles)</li></ul><p><em>Some conditions may influence the effects of Rucoron - for example:</em></p><ul><li>Low calcium levels in the blood</li><li>Low potassium levels in the blood</li><li>High magnesium levels in the blood</li><li>Low levels of protein in the blood</li><li>Too much carbon dioxide in the blood</li><li>Loss of too much water from the body, for example by being sick, diarrhoea or sweating</li><li>Over-breathing leading to too little carbon dioxide in the blood (alkalosis)</li><li>General ill-health</li><li>Burns</li><li>Being very overweight (obesity)</li><li>Very low body temperature (hypothermia).</li></ul><p>If you have any of these conditions, your anaesthetist will take it into account when deciding the correct dose of Rucoron for you.</p><p><strong>Children and elderly</strong><br />Rucoron can be used in children (newborns and adolescence) and elderly but your anaesthetist should first assess your medical history.</p><p><strong>Other medicines and Rucoron</strong><br />Tell your anaesthetist if you are taking other medicines or have recently taken them. This includes medicines or herbal products that you have bought without a prescription. Rucoron may affect other medicines or be affected by them.</p><p><em>Medicines which increase the effect of Rucoron:</em></p><ul><li>Certain antibiotics</li><li>Certain medicines for heart disease or high blood pressure (water tablets, calcium channel blockers, beta-blockers and quinidine)</li><li>Certain anti-inflammatory medicines (corticosteroids)</li><li>Medicines for manic depressive illness (bipolar disorder)</li><li>Magnesium salts</li><li>Certain medicines used to treat malaria.</li></ul><p><em>Medicines which decrease the effect of Rucoron:</em></p><ul><li>Certain medicines for epilepsy</li><li>Calcium chloride and potassium chloride</li><li>Certain protease inhibitors called gabexate and ulinastatin.</li></ul><p>In addition, you may be given other medicines before or during surgery which can alter the effects of Rucoron. These include certain anaesthetics, other muscle relaxants, medicines such as phenytoin and medicines which reverse the effects of Rucoron. Rucoron may make certain anaesthetics work more quickly. Your anaesthetist will take this into account when deciding the correct dose of Rucoron for you.</p><p><strong>Pregnancy and &nbsp;breast-feeding</strong><br />Tell your anaesthetist if you are pregnant or might be pregnant, or if you are breast feeding.</p><p>Your anaesthetist may still give you Rucoron, but you need to discuss it first. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your anaesthetist or other doctor for advice before taking this medicine. Rucoron may be given to you if you are having a Caesarean section.</p><p>Breastfeeding should be suspended 6 hours after use of this medicine.</p><p><strong>Driving and using machines</strong><br />Do not drive or use machines until advised it is safe to do so. Because Rucoron is given as part of a general anaesthetic, you may feel tired, weak or dizzy for some time afterwards. Your anaesthetist will be able to advise you on how long the effects are likely to last.</p><p><strong>Rucoron contains sodium</strong><br />Rucoron contains sodium. Each 5 ml of Rucoron 50 mg/5 ml Solution for Injection contains 0.355 mmol (8.165 mg) sodium. This medicine contains less than 1 mmol sodium (23 mg) per 5 ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Dose</strong><br />Your anaesthetist will work out the dose of Rucoron you need based on:</p><ul><li>The type of anaesthetic</li><li>The expected length of the operation</li><li>Other drugs you are taking</li><li>Your state of health.</li></ul><p>The normal dose is 0.6 mg per kg body weight and the effect will last 30&ndash;40 minutes.</p><p><strong>How </strong><strong>Rucoron is given</strong><br />Rucoron will be given to you by your anaesthetist. Rucoron is given intravenously (into a vein), either as single injections or as a continuous infusion (a drip).</p><p><strong>If you are given more </strong><strong>Rucoron than you should</strong><br />As your anaesthetist will be monitoring your condition carefully it is unlikely that you will be given too much Rucoron. However, if this happens, your anaesthetist will keep you breathing artificially (on a ventilator) until you can breathe on your own. You will be kept asleep while this takes place.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If these side effects occur while you are under anaesthetic, they will be seen and treated by your anaesthetist.</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><ul><li>The drug is too effective, or not effective enough</li><li>The drug works for longer than expected</li><li>Lowering of blood pressure</li><li>Increase in heart rate</li><li>Pain near the site of injection.</li></ul><p><strong>Very rare side effects (may affect up to 1 in 10,000 people)</strong></p><ul><li>Allergic (hypersensitivity) reactions (such as difficulty in breathing, collapse of the circulation and shock)</li><li>Wheezing of the chest</li><li>Muscle weakness</li><li>Swelling, a rash or redness of the skin.</li></ul><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><ul><li>Severe allergic coronary blood vessels spasm (Kounis syndrome) resulting in chest pain (angina) or heart attack (myocardial infarction).</li></ul><p>If any of the side effects gets serious or if you notice any side effects not listed in this leaflet, tell your anaesthetist or other doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store in a refrigerator (2-8&deg;C).</p><p>Store in the original package in order to protect from light.</p><p>The product can be stored outside of the refrigerator at a temperature of up to 25&deg;C for a maximum of 4 months. The product may be placed in and out the refrigerator at any point(s) during the 36 months shelf life, but the total storage time outside the refrigerator must not exceed 4 months. The storage period may not exceed the labeled shelf life.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient is rocuronium bromide.</p><p>Each 5 ml of Rucoron 50 mg/5 ml Solution for Injection contains 50 mg rocuronium bromide.</p><p>The other ingredients are sodium chloride, sodium acetate, acetic acid, sodium hydroxide and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rucoron 50 mg/5 ml Solution for Injection is a clear colourless to yellow/orange solution in 5 ml clear type I glass vials stoppered with rubber stoppers and sealed with aluminum flip-off caps. 

Pack size: 10 Vials (5 ml).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong><br />Hikma Farmaceutica (Portugal), S.A.<br />Estrada do Rio Da M&oacute;,<br />n.&deg;8, 8A e 8B, Ferven&ccedil;a<br />2705-906 Terrugem<br />Sintra, Portugal<br />Tel: + (351-2) 19608410<br />Fax: + (351-2) 19615102</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><p>&bull;&nbsp;&nbsp; Saudi Arabia<br />The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp; Other GCC States<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 06/2023; version number SA2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي روكورون إلى مجموعة الأدوية المسماة مرخيات العضلات.</p><p dir="RTL">تستخدم مرخيات العضلات خلال العمليات الجراحية كجزء من عملية التخدير العام. يجب أن تكون جميع عضلات الجسم مرتخية لديك أثناء خضوعك للعمليات الجراحية. حيث أنه يسهل ذلك على الطبيب القيام بإجراء العملية الجراحية.</p><p dir="RTL">عادة، يقوم روكورون باعتراض الأوامر العصبية المرسلة من الجهاز العصبي إلى العضلات، وهذا يساعد على ارتخاء العضلات. وحيث أنه يؤدي ذلك إلى ارتخاء العضلات المسؤولة عن عملية التنفس، ستحتاج للتنفس الاصطناعي خلال وبعد العملية الجراحية حتى تستعيد قدرتك على التنفس الذاتي.</p><p dir="RTL">سيقوم طبيب التخدير بمراقبة تأثير روكورون كمرخي للعضلات أثناء العملية الجراحية وقد يعطيك المزيد منه إذا تطلب الأمر. عند نهاية العملية الجراحية، تتناقص تأثيرات الدواء تدريجياً وستستعيد قدرتك على التنفس ذاتياً. في بعض الأحيان سيقوم طبيب التخدير بإعطائك دواء آخر للمساعدة في تسريع ذلك.</p><p dir="RTL">قد يستعمل روكورون في وحدات العناية المركزة لإبقاء عضلات المرضى بحالة استرخاء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا يجب عليك تلقي </strong><strong>روكورون</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية (فرط الحساسية) لروكورونيوم، أيون البروميد أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li></ul><p dir="RTL">أخبر طبيب التخدير الخاص بك إذا كان هذا ينطبق عليك.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات&nbsp;</strong><br /><em>تحدث مع طبيب التخدير</em><em> الخاص بك</em><em> </em><em>قبل أن تتلقى هذا الدواء</em><em>:</em></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لمرخيات العضلات</li><li>إذا كنت تعاني من أمراض في الكلى، القلب، الكبد أو المرارة</li><li>إذا كنت تعاني من أمراض تؤثر على الأعصاب أو العضلات</li><li>إذا كنت تعاني من احتباس السوائل في الجسم (وذمة)</li></ul><p>أخبر طبيب التخدير إذا انطبق عليك أي مما ذكر.</p><ul dir="rtl"><li>إذا كان لديك تاريخ مرضي بفرط الحرارة الخبيث (حرارة مفاجئة مع نبض سريع في القلب، تنفس سريع والتصلّب، ألم و/أو ضعف في عضلاتك)</li></ul><p dir="RTL"><em>قد تؤثر الحالات على فعالية روكورون - مثل:</em></p><ul dir="rtl"><li>انخفاض مستويات الكالسيوم في الدم</li><li>انخفاض مستويات البوتاسيوم في الدم</li><li>ارتفاع مستويات المغنيسيوم في الدم</li><li>انخفاض مستويات البروتين في الدم</li><li>ارتفاع تركيز ثاني أكسيد الكربون في الدم</li><li>فقدان كمية كبيرة من الماء من الجسم، على سبيل المثال في حالات التقيؤ، الإسهال أو التعرق</li><li>ارتفاع معدل التنفس والذي يؤدي إلى انخفاض تركيز ثاني أكسيد الكربون في الدم (القلاء)</li><li>الصحة العامة المتردية</li><li>الحروق</li><li>الوزن الزائد (السمنة)</li><li>انخفاض درجة حرارة الجسم.</li></ul><p dir="RTL">في حال انطبق عليك أي مما ذكر أعلاه، سيقوم طبيب التخدير الخاص بك بأخذ ذلك بعين الاعتبار عند تحديد الجرعة المناسبة من روكورون لك.</p><p dir="RTL"><strong>الأطفال وكبار السن&nbsp;</strong><br />يمكن استخدام روكورون لدى الأطفال (حديثي الولادة والمراهقين) وكبار السن ولكن يجب على طبيب التخدير الخاص بك بتقييم تاريخك الطبي قبل اعطاء هذا الدواء لك.</p><p dir="RTL"><strong>الأدوية الأخرى وروكورون&nbsp;</strong><br />أخبر طبيب التخدير الخاص بك إذا كنت تتناول أو تناولت مؤخراً أية أدوية أخرى، ويشمل هذا الأدوية أو المستحضرات العشبية التي تم الحصول عليها بدون وصفة طبية. قد يؤثر روكورون على فعالية الأدوية الأخرى أو قد تتأثر فعاليته بالأدوية الأخرى.</p><p dir="RTL"><em>الأدوية التي تزيد من تأثير روكورون:</em></p><ul dir="rtl"><li>أنواع محددة من المضادات الحيوية</li><li>أدوية محددة من أدوية أمراض القلب أو ارتفاع ضغط الدم (الأدوية المدرة للبول، حاصرات قنوات الكالسيوم، حاصرات بيتا، والكينيدين)</li><li>أنواع محددة من الأدوية المضادة للالتهاب (الستيرويدات القشرية)</li><li>الأدوية المستخدمة لعلاج اضطراب الهوس الاكتئابي (اضطراب ثنائي القطب)</li><li>أملاح المغنيسيوم</li><li>أنواع محددة من الأدوية المستخدمة لعلاج الملاريا.</li></ul><p dir="RTL"><em>الأدوية التي تقلل من تأثير روكورون:</em></p><ul dir="rtl"><li>أدوية محددة من مضادات الصرع</li><li>كلوريد الكالسيوم وكلوريد البوتاسيوم</li><li>أدوية محددة مثبطات البروتياز تسمى غابيكسات وأوليناستاتين.</li></ul><p dir="RTL">بالإضافة إلى ذلك، قد يتم اعطاؤك أدوية أخرى قبل أو خلال العملية الجراحية التي قد تغير من تأثيرات روكورون. تتضمن هذه الأدوية أنواع محددة من الأدوية المخدرة، الأدوية المرخية للعضلات الأخرى، الأدوية مثل الفينيتوين والأدوية التي تعكس تأثير روكورون. قد يسرع روكورون من بدأ تأثير أنواع محددة من الأدوية المرخية للعضلات. سيقوم طبيب التخدير الخاص بك بأخذ ذلك في بعين الاعتبار عند تحديد الجرعة الصحيحة من روكورون.</p><p dir="RTL"><strong>الحمل والرضاعة&nbsp;</strong><br />أخبري طبيب التخدير الخاص بك إذا كنت حاملاً أو تعتقدين بأنك حاملاً، أو كنت مرضعاً.</p><p dir="RTL">قد يقوم طبيب التخدير الخاص بك بإعطائك روكورون على جميع الأحوال، لكن عليك مناقشة ذلك أولاً. يجب عليك طلب النصيحة من طبيب التخدير الخاص بك قبل استخدام هذا الدواء، إذا كنت حاملاً أو مرضعاً، تعتقدين بأنك حاملاً أو تخططين لذلك. قد يعطى روكورون لك في حال كنت ستخضعين لعملية الولادة القيصرية.</p><p dir="RTL">يجب إيقاف الرضاعة لمدة 6 ساعات بعد استخدام هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات&nbsp;</strong><br />لا تقم بالقيادة أو استخدام الآلات حتى يتم اخبارك بمأمونية ذلك. لأن روكورون يعطى كجزء من التخدير العام، قد تشعر بالتعب، الضعف أو الدوخة لمدة قصيرة بعد ذلك. قد يقدم لك طبيب التخدير الخاص بك النصيحة حول المدة الزمنية التي قد تستغرقها التأثيرات قبل أن تتلاشى.</p><p dir="RTL"><strong>يحتوي روكورون على الصوديوم&nbsp;</strong><br />يحتوي روكورون على الصوديوم. تحتوي كل 5 مللتر من روكورون 50 ملغم/5 مللتر محلول للحقن على 0.355 ملمول (8.165 ملغم) صوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل 5 مللتر، وبذلك يمكن اعتباره أنه &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة&nbsp;</strong><br />سيقوم طبيب التخدير بتحديد الجرعة اللازمة من روكورون بالاعتماد على:</p><ul dir="rtl"><li>نوع المادة المخدرة</li><li>المدة المتوقعة للعملية الجراحية</li><li>الأدوية الأخرى التي تتناولها</li><li>الحالة الصحية العامة لديك.</li></ul><p dir="RTL">الجرعة الاعتيادية هي 0.6 ملغم لكل كغم من وزن الجسم ويستمر تأثيرها لمدة 30 إلى 40 دقيقة.</p><p dir="RTL"><strong>كيفية إعطاء روكورون&nbsp;</strong><br />سوف يعطى روكورون لك من قبل طبيب التخدير. يعطى روكورون عن طريق الوريد، إما كحقن مفردة أو كتسريب مستمر (بالتنقيط).</p><p dir="RTL"><strong>&nbsp;إذا تم إعطاؤك روكورون أكثر من اللازم&nbsp;</strong><br />من غير المحتمل إعطاؤك جرعة زائدة من روكورون حيث أن طبيب التخدير الخاص بك سوف يراقب حالتك بحذر. مع ذلك، إذا حدث ذلك لك سيقوم طبيبك بإبقائك تحت التنفس الاصطناعي (جهاز التنفس الاصطناعي) حتى تستعيد قدرتك على التنفس الذاتي. سوف يبقيك الطبيب نائماً طوال هذه الفترة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء. سيقوم طبيب التخدير الخاص بك بمراقبة حصول أي من هذه الآثار وعلاجها، إذا لزم الأمر، إذا حدثت هذه الآثار خلال فترة تخديرك.</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص)</strong></p><ul dir="rtl"><li>تأثير عالي للدواء، أو تأثير أقل من المطلوب</li><li>تأثير الدواء يبقى لفترة أطول من المتوقع</li><li>انخفاض ضغط الدم</li><li>ارتفاع معدل ضربات القلب</li><li>ألم حول موضع الحقن.</li></ul><p dir="RTL"><strong>الآثار الجانبية النادرة جداً (قد تؤثر على ما يصل إلى شخص واحد من كل 10000 شخص)</strong></p><ul dir="rtl"><li>ردود فعل تحسسية (فرط التحسس) (مثل صعوبة في التنفس، هبوط في الجهاز الدوراني وصدمة)</li><li>صفير في الصدر</li><li>ضعف العضلات</li><li>تورم، طفح جلدي أو احمرار الجلد.</li></ul><p dir="RTL"><strong>غير معروفة (</strong><strong>لا يمكن تقدير </strong><strong>التكرار</strong><strong> من البيانات المتوفرة)</strong></p><ul dir="rtl"><li>تشنج الأوعية الدموية التاجية التحسسي الحاد (متلازمة كونيس) مما يسبب ألم في الصدر (ذبحة) أو نوبة قلبية (احتشاء عضلة القلب).</li></ul><p dir="RTL">في حال اصبحت أي من الآثار الجانبية أكثر سوءاً أو في حال ظهور أية آثار جانبية جديدة لم تذكر في هذه النشرة، قم بأخبار طبيب التخدير الخاص بك أو طبيب آخر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ داخل الثلاجة (2-8˚ مئوية).</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">يمكن تخزين المستحضر خارج الثلاجة عند درجة حرارة تصل إلى 25&deg; مئوية لمدة أقصاها 4 أشهر. يمكن وضع المستحضر داخل وخارج الثلاجة في أي وقت (فترات) خلال مدة الصلاحية البالغة 36 شهراً، ولكن يجب ألا يتجاوز إجمالي وقت التخزين خارج الثلاجة 4 أشهر. يجب ألا تتجاوز فترة التخزين مدة الصلاحية.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي بروميد الروكورونيوم.</p><p dir="RTL">تحتوي كل 5 مللتر من روكورون 50 ملغم/5 مللتر محلول للحقن على ٥٠ ملغم بروميد الروكورونيوم.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي كلوريد الصوديوم، أسیتات الصوديوم، حمض الأسيتيك، هيدروكسيد الصوديوم وماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">روكورون 50 ملغم/5 مللتر محلول للحقن هو محلول صافٍ عديم اللون مائل إلى الأصفر/البرتقالي في زجاجات شفافة بحجم 5 مللتر من النوع رقم واحد مع سدادات مطاطية ومحكمة الإغلاق بأغطية من الألومنيوم قابلة للفتح لأعلى.</p><p dir="RTL">&nbsp;حجم العبوة: 10 زجاجات (5 مللتر).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق&nbsp;</strong><br />شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة&nbsp;</strong><br />شركة أدوية الحكمة (البرتغال)<br />إسترادا دو ريو دا مو،<br /><img src="data:image/png;base64,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" alt="" width="136" height="15" vspace="0" hspace="0" border="0" style="width:136px;height:15px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /><br />2705-906&nbsp;تيروجيم<br />سنترا، البرتغال<br />هاتف: 19608410 (2-351) +<br />فاكس: 19615102 (2-351) +</p><p><strong>للإبلاغ عن الآثار الجانبية&nbsp;</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><p dir="RTL">&bull;&nbsp;المملكة العربية السعودية&nbsp;<br />المركز الوطني للتيقظ الدوائي<br />مركز الاتصال الموحد: 19999<br />البريد الإلكتروني: npc.drug@sfda.gov.sa<br />الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&bull; دول الخليج العربي الأخرى<br />الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 06/2023؛ رقم النسخة SA2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rucoron 50 mg/5 ml Solution for Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 ml contains 50 mg rocuronium bromide.

Excipients with known effect: Sodium.
 
For a full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for Injection.

Clear colourless to yellow/orange solution.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rucoron is indicated in adult and paediatric patients (from term neonates to adolescents [0 to &lt; 18 years]) as an adjunct to general anaesthesia to facilitate tracheal intubation during routine sequence induction and to provide skeletal muscle relaxation during surgery. In adults Rucoron is also indicated to facilitate tracheal intubation during rapid sequence induction and as an adjunct in the intensive care unit (ICU) to facilitate intubation and mechanical ventilation.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong><br />Like other neuromuscular blocking agents, Rucoron should only be administered by, or under supervision of, experienced clinicians who are familiar with the action and use of these drugs.</p><p>As with other neuromuscular blocking agents, the dosage of Rucoron should be individualised in each patient. The method of anaesthesia and the expected duration of surgery, the method of sedation and the expected duration of mechanical ventilation, the possible interaction with other drugs that are administered concomitantly, and the condition of the patient should be taken into account when determining the dose.</p><p>The use of an appropriate neuromuscular monitoring technique is recommended for the evaluation of neuromuscular block and recovery.</p><p>Inhalational anaesthetics do potentiate the neuromuscular blocking effects of rocuronium bromide. This potentiation however, becomes clinically relevant in the course of anaesthesia, when the volatile agents have reached the tissue concentrations required for this interaction. Consequently, adjustments with Rucoron should be made by administering smaller maintenance doses at less frequent intervals or by using lower infusion rates of Rucoron during long lasting procedures (longer than 1 hour) under inhalational anaesthesia (see section 4.5).</p><p>In adult patients the following dosage recommendations may serve as a general guideline for tracheal intubation and muscle relaxation for short to long lasting surgical procedures and for use in the intensive care unit.</p><ul><li>Surgical Procedures</li></ul><p><em>Tracheal intubation</em><br />The standard intubating dose during routine anaesthesia is 0.6 mg/kg rocuronium bromide, after which adequate intubation conditions are established within 60 seconds in nearly all patients. A dose of 1.0 mg/kg rocuronium bromide is recommended for facilitating tracheal intubation conditions during rapid sequence induction of anaesthesia, after which adequate intubation conditions are established within 60 seconds in nearly all patients. If a dose of 0.6 mg/kg rocuronium bromide is used for rapid sequence induction of anaesthesia, it is recommended to intubate the patient 90 seconds after administration of rocuronium bromide.</p><p>For use of rocuronium bromide during rapid sequence induction of anaesthesia in patients undergoing Caesarean section reference is made to section 4.6.</p><p><em>Higher doses</em><br />Should there be reason for selection of larger doses in individual patients, there is no indication from clinical studies that the use of initial doses up to 2 mg/kg rocuronium bromide is associated with an increased frequency or severity of cardiovascular effects. The use of these high dosages of rocuronium bromide decreases the onset time and increases the duration of action (see section 5.1).</p><p><em>Maintenance dosing</em><br />The recommended maintenance dose is 0.15 mg/kg rocuronium bromide; in the case of long-term inhalational anaesthesia this should be reduced to 0.075-0.1 mg/kg rocuronium bromide. The maintenance doses should best be given when twitch height has recovered to 25% of control twitch height, or when 2 to 3 responses to train of four stimulation are present.</p><p><em>Continuous infusion</em><br />If rocuronium bromide is administered by continuous infusion, it is recommended to give a loading dose of 0.6 mg/kg rocuronium bromide and, when neuromuscular block starts to recover, to start administration by infusion. The infusion rate should be adjusted to maintain twitch response at 10% of control twitch height or to maintain 1 to 2 responses to train of four stimulation. In adults under intravenous anaesthesia, the infusion rate required to maintain neuromuscular block at this level ranges from 0.3-0.6 mg/kg/h (300-600 micrograms/kg/h) and under inhalational anaesthesia the infusion rate ranges from 0.3-0.4 mg/kg/h. Continuous monitoring of neuromuscular block is essential since infusion rate requirements vary from patient to patient and with the anaesthetic method used.</p><p><em>Paediatric population</em><br />For neonates (0-27 days), infants (28 days-2 months), toddlers (3-23 months), children (2-11 years) and adolescents (12-17 years) the recommended intubation dose during routine anaesthesia and maintenance dose are similar to those in adults.</p><p>However, the duration of action of the single intubating dose will be longer in neonates and infants than in children (see section 5.1).</p><p>For continuous infusion in paediatrics, the infusion rates, with the exception of children (2-11 years), are the same as for adults. For children aged 2-11 years higher infusion rates might be necessary.</p><p>Thus, for children (2-11 years) the same initial infusion rates as for adults are recommended and then this should be adjusted to maintain twitch response at 10% of control twitch height or to maintain 1 or 2 responses to train of four stimulation during the procedure.</p><p>The experience with rocuronium bromide in rapid sequence induction in paediatric patients is limited. Rocuronium bromide is therefore not recommended for facilitating tracheal intubation conditions during rapid sequence induction in paediatric patients.</p><p><em>Geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure</em><br />The standard intubation dose for geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure during routine anaesthesia is 0.6 mg/kg rocuronium bromide. A dose of 0.6 mg/kg should be considered for rapid sequence induction of anaesthesia in patients in which a prolonged duration of action is expected. Regardless of the anaesthetic technique used, the recommended maintenance dose for these patients is 0.075-0.1 mg/kg rocuronium bromide, and the recommended infusion rate is 0.3-0.4 mg/kg/h (see Continuous infusion) (see also section 4.4).</p><p><em>Overweight and obese patients</em><br />When used in overweight or obese patients (defined as patients with a body weight of 30% or more above ideal body weight) doses should be reduced taking into account ideal body weight.</p><ul><li>Intensive Care Procedures</li></ul><p><em>Tracheal intubation</em><br />For tracheal intubation, the same doses should be used as described above under surgical procedures.</p><p><em>Maintenance dosing</em><br />The use of an initial loading dose of 0.6 mg/kg rocuronium bromide is recommended, followed by a continuous infusion as soon as twitch height recovers to 10% or upon reappearance of 1 to 2 twitches to train of four stimulation. Dosage should always be titrated to effect in the individual patient. The recommended initial infusion rate for the maintenance of a neuromuscular block of 80-90% (1 to 2 twitches to TOF stimulation) in adult patients is 0.3-0.6 mg/kg/h during the first hour of administration, which will need to be decreased during the following 6-12 hours, according to the individual response. Thereafter, individual dose requirements remain relatively constant.</p><p>A large between patient variability in hourly infusion rates has been found in controlled clinical studies, with mean hourly infusion rates ranging from 0.2-0.5 mg/kg/h depending on nature and extent of organ failure(s), concomitant medication and individual patient characteristics. To provide optimal individual patient control, monitoring of neuromuscular transmission is strongly recommended. Administration up to 7 days has been investigated.</p><p><em>Special populations</em><br />Rocuronium bromide is not recommended for the facilitation of mechanical ventilation in the intensive care in paediatric and geriatric patients due to a lack of data on safety and efficacy.</p><p><strong>Method of administration</strong><br />Rucoron is administered intravenously either as a bolus injection or as a continuous infusion (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to rocuronium bromide or to the bromide ion or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since rocuronium bromide causes paralysis of the respiratory muscles, ventilatory support is mandatory for patients treated with this drug until adequate spontaneous respiration is restored. As with all neuromuscular blocking agents, it is important to anticipate intubation difficulties, particularly when used as part of a rapid sequence induction technique.</p><p>As with other neuromuscular blocking agents, residual neuromuscular blockade has been reported for rocuronium bromide. In order to prevent complications resulting from residual neuromuscular blockade, it is recommended to extubate only after the patient has recovered sufficiently from neuromuscular block. Geriatric patients (65 years or older) may be at increased risk for residual neuromuscular block. Other factors which could cause residual neuromuscular blockade after extubation in the post-operative phase (such as drug interactions or patient condition) should also be considered. If not used as part of standard clinical practice, the use of a reversal agent (such as sugammadex or acetylcholinesterase inhibitors) should be considered, especially in those cases where residual neuromuscular blockade is more likely to occur.</p><p>High rates of cross-sensitivity between neuromuscular blocking agents have been reported. Therefore, where possible, before administering rocuronium bromide, hypersensitivity to other neuromuscular blocking agents should be excluded. Rocuronium bromide should only be used when absolutely essential in susceptible patients. Patients who experience a hypersensitivity reaction under general anaesthesia should be tested subsequently for hypersensitivity to other neuromuscular blockers.</p><p>Rocuronium bromide may increase the heart rate.</p><p>In general, following long term use of neuromuscular blocking agents in the ICU, prolonged paralysis and/or skeletal muscle weakness has been noted. In order to help preclude possible prolongation of neuromuscular block and/or overdosage it is strongly recommended that neuromuscular transmission is monitored throughout the use of neuromuscular blocking agents. In addition, patients should receive adequate analgesia and sedation. Furthermore, neuromuscular blocking agents should be titrated to effect in the individual patients by or under supervision of experienced clinicians who are familiar with their actions and with appropriate neuromuscular monitoring techniques.</p><p>Myopathy after long term administration of other non-depolarising neuromuscular blocking agents in the ICU in combination with corticosteroid therapy has been reported regularly. Therefore, for patients receiving both neuromuscular blocking agents and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible.</p><p>If suxamethonium is used for intubation, the administration of Rucoron should be delayed until the patient has clinically recovered from the neuromuscular block induced by suxamethonium.</p><p>Because rocuronium bromide is always used with other drugs and because of the risk of malignant hyperthermia during anesthesia, even in the absence of known triggering factors, physicians should be aware of the early symptoms, confirmatory diagnosis and treatment of malignant hyperthermia prior to the start of anesthesia. Animal studies have shown that rocuronium bromide is not a triggering factor for malignant hyperthermia. Rare cases of malignant hyperthermia with rocuronium bromide have been observed thru post-marketing surveillance; however, the causal association has not been proven.</p><p><strong>The following conditions may influence the pharmacokinetics and/or pharmacodynamics of </strong><strong>rocuronium bromide:</strong><br /><em>Hepatic and/or biliary tract disease and renal failure</em><br />Because rocuronium bromide is excreted in urine and bile, it should be used with caution in patients with clinically significant hepatic and/or biliary diseases and/or renal failure. In these patient groups prolongation of action has been observed with doses of 0.6 mg/kg rocuronium bromide.</p><p><em>Prolonged circulation time</em><br />Conditions associated with prolonged circulation time such as cardiovascular disease, old age and oedematous state resulting in an increased volume of distribution, may contribute to a slower onset of action. The duration of action may also be prolonged due to a reduced plasma clearance.</p><p><em>Neuromuscular disease</em><br />Like other neuromuscular blocking agents, rocuronium bromide should be used with extreme caution in patients with a neuromuscular disease or after poliomyelitis since the response to neuromuscular blocking agents may be considerably altered in these cases. The magnitude and direction of this alteration may vary widely. In patients with myasthenia gravis or with the myasthenic (Eaton-Lambert) syndrome, small doses of rocuronium bromide may have profound effects and rocuronium bromide should be titrated to the response.</p><p><em>Hypothermia</em><br />In surgery under hypothermic conditions, the neuromuscular blocking effect of rocuronium bromide is increased and the duration prolonged.</p><p><em>Obesity</em><br />Like other neuromuscular blocking agents, rocuronium bromide may exhibit a prolonged duration and a prolonged spontaneous recovery in obese patients when the administered doses are calculated on actual body weight.</p><p><em>Burns</em><br />Patients with burns are known to develop resistance to non-depolarising neuromuscular blocking agents. It is recommended that the dose is titrated to response.</p><p><em>Conditions which may increase the effects of rocuronium bromide</em><br />Hypokalaemia (e.g. after severe vomiting, diarrhoea and diuretic therapy), hypermagnesaemia, hypocalcaemia (after massive transfusions), hypoproteinaemia, dehydration, acidosis, hypercapnia, cachexia.</p><p>Severe electrolyte disturbances, altered blood pH or dehydration should therefore be corrected when possible.</p><p><strong>Rucoron contains sodium</strong><br />Rucoron contains sodium. Each 5 ml contains 0.355 mmol (8.165 mg) sodium. This medicine contains less than 1 mmol sodium (23 mg) per 5 ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following drugs have been shown to influence the magnitude and/or duration of action of non-depolarising neuromuscular blocking agents.</p><p><strong>Effect of other drugs on rocuronium bromide</strong><br /><em>Increased effect:</em></p><ul><li>Halogenated volatile anaesthetics potentiate the neuromuscular block of rocuronium bromide. The effect only becomes apparent with maintenance dosing (see section 4.2). Reversal of the block with acetylcholinesterase inhibitors could also be inhibited.</li><li>After intubation with suxamethonium (see section 4.4).</li><li>Long-term concomitant use of corticosteroids and rocuronium bromide in the ICU may result in prolonged duration of neuromuscular block or myopathy (see section 4.4 and 4.8).</li></ul><p>Other drugs:</p><ul><li>Antibiotics: aminoglycoside, lincosamide and polypeptide antibiotics, acylamino-penicillin antibiotics.</li><li>Diuretics, quinidine and its isomer quinine, magnesium salts, calcium channel blocking agents, lithium salts, local anaesthetics (lidocaine i.v, bupivacaine epidural) and acute administration of phenytoin or &szlig;-blocking agents.</li></ul><p>Recurarisation has been reported after post-operative administration of: aminoglycoside, lincosamide, polypeptide and acylamino-penicillin antibiotics, quinidine, quinine and magnesium salts (see section 4.4).</p><p><em>Decreased effect:</em></p><ul><li>Prior chronic administration of phenytoin or carbamazepine.</li><li>Calcium chloride, potassium chloride.</li><li>Protease inhibitors (gabexate, ulinastatin).</li></ul><p><em>Variable effect: </em></p><ul><li>Administration of other non-depolarising neuromuscular blocking agents in combination with rocuronium bromide may produce attenuation or potentiation of the neuromuscular block, depending on the order of administration and the neuromuscular blocking agent used.</li><li>Suxamethonium given after the administration of rocuronium bromide may produce potentiation or attenuation of the neuromuscular blocking effect of rocuronium bromide.</li></ul><p><strong>Effect of rocuronium bromide on other drugs</strong><br />Rucoron combined with lidocaine may result in a quicker onset of action of lidocaine.</p><p><em>Paediatric population</em><br />No formal interaction studies have been performed. The above mentioned interactions for adults and their special warnings and precautions for use (see section 4.4) should be taken into account for paediatric patients</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br />For rocuronium bromide, no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Caution should be exercised when prescribing rocuronium bromide to pregnant women.</p><p><strong>Caesarean section</strong><br />In patients undergoing Caesarean section, rocuronium bromide can be used as part of a rapid sequence induction technique, provided no intubation difficulties are anticipated and a sufficient dose of anaesthetic agent is administered or following suxamethonium facilitated intubation. However, rocuronium bromide, administered in doses of 0.6 mg/kg may not produce adequate conditions for intubation until 90 seconds after administration. This dose has been shown to be safe in parturients undergoing Caesarean section. Rocuronium bromide does not affect Apgar score, foetal muscle tone or cardiorespiratory adaptation. From umbilical cord blood sampling it is apparent that only limited placental transfer of rocuronium bromide occurs which does not lead to the observation of clinical adverse effects in the newborn.</p><p>Note 1: doses of 1.0 mg/kg have been investigated during rapid sequence induction of anaesthesia, but not in Caesarean section patients. Therefore, only a dose of 0.6 mg/kg is recommended in this patient group.</p><p>Note 2: Reversal of neuromuscular block induced by neuromuscular blocking agents may be inhibited or unsatisfactory in patients receiving magnesium salts for toxemia of pregnancy because magnesium salts enhance neuromuscular blockade. Therefore, in these patients the dosage of rocuronium bromide should be reduced and be titrated to twitch response.</p><p><strong>Breast-feeding</strong><br />It is unknown whether rocuronium bromide is excreted in human breast milk. Animal studies have shown insignificant levels of rocuronium bromide in breast milk.</p><p>Insignificant levels of rocuronium bromide were found in the milk of lactating rats. There are no human data on the use of rocuronium bromide during lactation. Rucoron should be given to lactating women only when the attending physician decides that the benefits outweigh the risks. After the administration of a single dose, it is recommended to abstain from next breastfeeding for five elimination half-lives of rocuronium bromide, i.e. for about 6 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since Rucoron is used as an adjunct to general anaesthesia, the usual precautionary measures after a general anaesthesia should be taken for ambulatory patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong><br />The most commonly occurring adverse drug reactions include injection site pain/reaction, changes in vital signs and prolonged neuromuscular block. The most frequently reported serious adverse drug reactions during post-marketing surveillance is &#39;anaphylactic and anaphylactoid reactions&#39; and associated symptoms. See also the explanations below the table.</p><p><strong>Tabulated list of adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA SOC</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Preferred term<sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Uncommon/rare<sup>2</sup> (&lt;1/100, &gt;1/10,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare (&lt;1/10,000)</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Immune system disorders</p></td><td rowspan="5" style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactoid reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic shock</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactoid shock</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Flaccid paralysis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Kounis syndrome</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td rowspan="2" style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Circulatory collapse and shock</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bronchospasm</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td rowspan="4" style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Angioneurotic oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Erythematous rash</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td rowspan="2" style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Muscular weakness<sup>3</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Steroid myopathy<sup>3</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Drug ineffective</p></td><td rowspan="5" style="vertical-align:top"><p>Face oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Drug effect/ therapeutic response decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Drug effect/ therapeutic response increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection site pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection site reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Prolonged neuromuscular block</p></td><td style="vertical-align:top"><p>Airway complication of anaesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Delayed recovery from anaesthesia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>MedDRA version 8.1</p><p><strong>Anaphylaxis</strong><br />Although very rare, severe anaphylactic reactions to neuromuscular blocking agents, including rocuronium bromide, have been reported. Anaphylactic/anaphylactoid reactions are: bronchospasm, cardiovascular changes (e.g. hypotension, tachycardia, circulatory collapse &ndash; shock), and cutaneous changes (e.g. angioedema, urticaria). These reactions have, in some cases, been fatal. Due to the possible severity of these reactions, one should always assume they may occur and take the necessary precautions.</p><p>Since neuromuscular blocking agents are known to be capable of inducing histamine release both locally at the site of injection and systemically, the possible occurrence of itching and erythematous reaction at the site of injection and/or generalised histaminoid (anaphylactoid) reactions (see also under anaphylactic reactions above) should always be taken into consideration when administering these drugs.</p><p>In clinical studies only a slight increase in mean plasma histamine levels has been observed following rapid bolus administration of 0.3-0.9 mg/kg rocuronium bromide.</p><p><strong>Prolonged neuromuscular block</strong><br />The most frequent adverse reaction to nondepolarising blocking agents as a class consists of an extension of the drug&#39;s pharmacological action beyond the time period needed. This may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency or apnea.</p><p><strong>Myopathy</strong><br />Myopathy has been reported after the use of various neuromuscular blocking agents in the ICU in combination with corticosteroids (see section 4.4).</p><p><strong>Local injection site reactions</strong><br />During rapid sequence induction of anaesthesia, pain on injection has been reported, especially when the patient has not yet completely lost consciousness and particularly when propofol is used as the induction agent. In clinical studies, pain on injection has been noted in 16% of the patients who underwent rapid sequence induction of anaesthesia with propofol and in less than 0.5% of the patients who underwent rapid sequence induction of anaesthesia with fentanyl and thiopental.</p><p><strong>Paediatric population</strong><br />A meta-analysis of 11 clinical studies in paediatric patients (n=704) with rocuronium bromide (up to 1 mg/kg) showed that tachycardia was identified as adverse drug reaction with a frequency of 1.4%.</p><p><sup>1</sup>Frequencies are estimates derived from post-marketing surveillance reports and data from the general literature.<br /><sup>2</sup>Post-marketing surveillance data cannot give precise incidence figures. For that reason, the reporting frequency was divided over two rather than five categories.<br /><sup>3</sup>After long-term use in the ICU</p><p><u>Reporting of suspected adverse reactions</u><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;Saudi Arabia<br />The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa<br />&bull;&nbsp;&nbsp; Other GCC States<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdosage and prolonged neuromuscular block, the patient should continue to receive ventilatory support and sedation. There are two options for the reversal of neuromuscular block: (1) In adults, sugammadex can be used for reversal of intense (profound) and deep block. The dose of sugammadex to be administered depends on the level of neuromuscular block. (2) An acetylcholinesterase inhibitor (e.g. neostigmine, edrophonium, pyridostigmine) or sugammadex can be used once spontaneous recovery starts and should be administered in adequate doses. When administration of an acetylcholinesterase inhibiting agent fails to reverse the neuromuscular effects of rocuronium bromide, ventilation must be continued until spontaneous breathing is restored. Repeated dosage of an acetylcholinesterase inhibitor can be dangerous.</p><p>In animal studies, severe depression of cardiovascular function, ultimately leading to cardiac collapse did not occur until a cumulative dose of 750 x ED<sub>90</sub> (135 mg/kg rocuronium bromide) was administered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Muscle relaxants, peripherally acting agents, ATC code: M03AC09.</p><p><strong>Mechanism of action</strong><br />Rucoron (rocuronium bromide) is a fast onset, intermediate acting non-depolarising neuromuscular blocking agent, possessing all of the characteristic pharmacological actions of this class of drugs (curariform). It acts by competing for nicotinic cholinoceptors at the motor end-plate. This action is antagonised by acetylcholinesterase inhibitors such as neostigmine, edrophonium and pyridostigmine.</p><p><strong>Pharmacodynamic effects</strong><br />The ED<sub>90</sub> (dose required to produce 90% depression of the twitch response of the thumb to stimulation of the ulnar nerve) during intravenous anaesthesia is approximately 0.3 mg/kg rocuronium bromide. The ED<sub>95</sub> in infants is lower than in adults and children (0.25, 0.35 and 0.40 mg/kg respectively).</p><p>The clinical duration (the duration until spontaneous recovery to 25% of control twitch height) with 0.6 mg/kg rocuronium bromide is 30&ndash;40 minutes. The total duration (time until spontaneous recovery to 90% of control twitch height) is 50 minutes. The mean time of spontaneous recovery of twitch response from 25 to 75% (recovery index) after a bolus dose of 0.6 mg/kg rocuronium bromide is 14 minutes. With lower dosages of 0.3-0.45 mg/kg rocuronium bromide (1 -1&frac12; x ED<sub>90</sub>), onset of action is slower and duration of action is shorter. With high doses of 2 mg/kg, clinical duration is 110 minutes.</p><p><strong>Intubation during routine anaesthesia</strong><br />Within 60 seconds following intravenous administration of a dose of 0.6 mg/kg rocuronium bromide (2 x ED<sub>90</sub> under intravenous anaesthesia), adequate intubation conditions can be achieved in nearly all patients of which in 80% intubation conditions are rated excellent. General muscle paralysis adequate for any type of procedure is established within 2 minutes. After administration of 0.45 mg/kg rocuronium bromide, acceptable intubation conditions are present after 90 seconds.</p><p><strong>Rapid sequence induction</strong><br />During rapid sequence induction of anaesthesia under propofol or fentanyl/thiopental anaesthesia, adequate intubation conditions are achieved within 60 seconds in 93% and 96% of the patients respectively, following a dose of 1.0 mg/kg rocuronium bromide. Of these, 70% are rated excellent. The clinical duration with this dose approaches 1 hour, at which time the neuromuscular block can be safely reversed. Following a dose of 0.6 mg/kg rocuronium bromide, adequate intubation conditions are achieved within 60 seconds in 81% and 75% of the patients during a rapid sequence induction technique with propofol or fentanyl/thiopental, respectively.</p><p><strong>Paediatric population</strong><br />Mean onset time in infants, toddlers and children at an intubation dose of 0.6 mg/kg is slightly shorter than in adults. Comparison within paediatric age groups showed that the mean onset time in neonates and adolescents (1.0 min.) is slightly longer than in infants, toddlers and children (0.4, 0.6 and 0.8 min., respectively). The duration of relaxation and the time to recovery tend to be shorter in children compared to infants and adults. Comparing within paediatric age groups demonstrated that mean time to reappearance of T<sub>3</sub> was prolonged in neonates and infants (56.7 and 60.7 min., respectively) when compared to toddlers, children and adolescents (45.4, 37.6 and 42.9 min., respectively).</p><p>Mean (SD) time to onset and clinical duration following 0.6 mg/kg rocuronium bromide initial intubating dose* during sevoflurane/nitrous oxide and isoflurane/nitrous oxide (maintenance) anaesthesia (Paediatric patients) <u>PP group</u></p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:100%"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Time to maximum block **</strong></p><p><strong>(min)</strong></p></td><td style="vertical-align:top"><p><strong>Time to reappearance of T3 ** (min)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Neonates (0-27 days)</p><p>n=10</p></td><td style="vertical-align:top"><p>0.98 (0.62)</p></td><td style="vertical-align:top"><p>56.69 (37.04)</p><p>n=9</p></td></tr><tr><td style="vertical-align:top"><p>Infants (28 days-2 months)</p><p>n=11</p></td><td style="vertical-align:top"><p>0.44 (0.19)</p><p>n=10</p></td><td style="vertical-align:top"><p>60.71 (16.52)</p></td></tr><tr><td style="vertical-align:top"><p>Toddler (3 months-23 months)</p><p>n=28</p></td><td style="vertical-align:top"><p>0.59 (0.27)</p></td><td style="vertical-align:top"><p>45.46 (12.94)</p><p>n=27</p></td></tr><tr><td style="vertical-align:top"><p>Children (2-11 years)</p><p>n=34</p></td><td style="vertical-align:top"><p>0.84 (0.29)</p></td><td style="vertical-align:top"><p>37.58 (11.82)</p></td></tr><tr><td style="vertical-align:top"><p>Adolescents (12-17 years)</p><p>n=31</p></td><td style="vertical-align:top"><p>0.98 (0.38)</p></td><td style="vertical-align:top"><p>42.90 (15.83)</p><p>n=30</p></td></tr></tbody></table><p><br />* Dose of rocuronium bromide administered within 5 seconds.<br />** Calculated from the end of administration of the rocuronium bromide intubating dose</p><p><strong>Geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure</strong><br />The duration of action of maintenance doses of 0.15 mg/kg rocuronium bromide might be somewhat longer under enflurane and isoflurane anaesthesia in geriatric patients and in patients with hepatic and/or renal disease (approximately 20 minutes) than in patients without impairment of excretory organ functions under intravenous anaesthesia (approximately 13 minutes) (see section 4.2). No accumulation of effect (progressive increase in duration of action) with repetitive maintenance dosing at the recommended level has been observed.</p><p><strong>Intensive Care Unit</strong><br />Following continuous infusion in the Intensive Care Unit, the time to recovery of the train of four ratio to 0.7 depends on the level of block at the end of the infusion. After a continuous infusion for 20 hours or more the median (range) time between return of T<sub>2</sub> to train of four stimulation and recovery of the train of four ratio to 0.7 approximates 1.5 (1-5) hours in patients without multiple organ failure and 4 (1-25) hours in patients with multiple organ failure.</p><p><strong>Cardiovascular surgery</strong><br />In patients scheduled for cardiovascular surgery the most common cardiovascular changes during the onset of maximum block following 0.6-0.9 mg/kg rocuronium bromide are a slight and clinically insignificant increase in heart rate up to 9% and an increase in mean arterial blood pressure up to 16% from the control values.</p><p><strong>Reversal of muscle relaxation</strong><br />Administration of acetylcholinesterase inhibitors, (neostigmine, pyridostigmine or edrophonium) at reappearance of T<sub>2</sub> or at the first signs of clinical recovery, antagonises the action of rocuronium bromide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After intravenous administration of a single bolus dose of rocuronium bromide the plasma concentration time course runs in three exponential phases. In normal adults, the mean (95% CI) elimination half-life is 73 (66-80) minutes, the (apparent) volume of distribution at steady state conditions is 203 (193-214) ml/kg and plasma clearance is 3.7 (3.5-3.9) ml/kg/min.</p><p>Rocuronium bromide is excreted in urine and bile. Excretion in urine approaches 40% within 12-24 hours. After injection of a radiolabeled dose of rocuronium bromide, excretion of the radiolabel is on average 47% in urine and 43% in faeces after 9 days. Approximately 50% is recovered as the parent compound. No metabolites are detected in plasma.</p><p><strong>Paediatric population</strong><br />Pharmacokinetics of rocuronium bromide in paediatric patients (n=146) with ages ranging from 0 to 17 years were evaluated using a population analysis of the pooled pharmacokinetic datasets from two clinical trials under sevoflurane (induction) and isoflurane/nitrous oxide (maintenance) anesthesia. All pharmacokinetic parameters were found to be linearly proportional to body weight illustrated by a similar clearance (l.hr<sup>-1</sup>.kg<sup>-1</sup>). The volume of distribution (l.kg<sup>-1</sup>) and elimination half-life (h) decrease with age (years). The pharmacokinetic parameters of typical paediatrics within each age group are summarized below:</p><p>Estimated PK parameters (Mean [SD]) of rocuronium bromide in typical paediatric patients during sevoflurane and nitrous oxide (induction) and isoflurane/nitrous oxide (maintenance anaesthesia)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>PK Parameters</p></td><td colspan="5" style="vertical-align:top"><p><strong>Patient age range</strong></p></td></tr><tr><td style="vertical-align:top"><p>Term newborn infants</p><p>(0-27 days)</p></td><td style="vertical-align:top"><p>Infants</p><p>(28 days to 2 months)</p></td><td style="vertical-align:top"><p>Toddlers</p><p>(3-23 months)</p></td><td style="vertical-align:top"><p>Children</p><p>(2-11 years)</p></td><td style="vertical-align:top"><p>Adolescents</p><p>(12-17 years)</p></td></tr><tr><td style="vertical-align:top"><p>CL (L/kg/hr)</p></td><td style="vertical-align:top"><p>0.31 (0.07)</p></td><td style="vertical-align:top"><p>0.30 (0.08)</p></td><td style="vertical-align:top"><p>0.33 (0.10)</p></td><td style="vertical-align:top"><p>0.35 (0.09)</p></td><td style="vertical-align:top"><p>0.29 (0.14)</p></td></tr><tr><td style="vertical-align:top"><p>Volume of distribution (L/kg)</p></td><td style="vertical-align:top"><p>0.42 (0.06)</p></td><td style="vertical-align:top"><p>0.31 (0.03)</p></td><td style="vertical-align:top"><p>0.23 (0.03)</p></td><td style="vertical-align:top"><p>0.18 (0.02)</p></td><td style="vertical-align:top"><p>0.18 (0.01)</p></td></tr><tr><td style="vertical-align:top"><p>t <sub>&frac12;</sub> <em>&beta;</em> (hr)</p></td><td style="vertical-align:top"><p>1.1 (0.2)</p></td><td style="vertical-align:top"><p>0.9 (0.3)</p></td><td style="vertical-align:top"><p>0.8 (0.2)</p></td><td style="vertical-align:top"><p>0.7 (0.2)</p></td><td style="vertical-align:top"><p>0.8 (0.3)</p></td></tr></tbody></table><p><strong>Geriatric patients and patients with hepatic and/or biliary tract disease and/or renal failure</strong><br />In controlled studies the plasma clearance in geriatric patients and in patients with renal dysfunction was reduced, in most studies however without reaching the level of statistical significance. In patients with hepatic disease, the mean elimination half-life is prolonged by 30 minutes and the mean plasma clearance is reduced by 1 ml/kg/min. (See section 4.2).</p><p><strong>Intensive Care Unit</strong><br />When administered as a continuous infusion to facilitate mechanical ventilation for 20 hours or more, the mean elimination half-life and the mean (apparent) volume of distribution at steady state are increased. A large between patient variability is found in controlled clinical studies, related to nature and extent of (multiple) organ failure and individual patient characteristics. In patients with multiple organ failure a mean (&plusmn; SD) elimination half-life of 21.5 (&plusmn; 3.3) hours, a (apparent) volume of distribution at steady state of 1.5 (&plusmn; 0.8) l/kg and a plasma clearance of 2.1 (&plusmn; 0.8) ml/kg/min were found. (See section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.</p><p>There is no proper animal model to mimic the usually extremely complex clinical situation of the ICU patient. Therefore the safety of rocuronium bromide when used to facilitate mechanical ventilation in the Intensive Care Unit is mainly based on results obtained in clinical studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Sodium acetate</li><li>Sodium chloride</li><li>Acetic acid</li><li>Sodium hydroxide</li><li>Water for injection</li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Physical incompatibility has been documented for rocuronium bromide when added to solutions containing the following drugs: amphotericin, amoxicillin<strong>, </strong>azathioprine, cefazolin, cloxacillin, dexamethasone, diazepam, enoximone, erythromycin, famotidine, furosemide, hydrocortisone sodium succinate, insulin, intralipid, methohexital, methylprednisolone, prednisolone sodium succinate, thiopental, trimethoprim and vancomycin.</p><p>Rucoron must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>If rocuronium bromide is administered via the same infusion line that is also used for other drugs, it is important that this infusion line is adequately flushed (e.g. with 0.9% NaCl) between administration of rocuronium bromide and drugs for which incompatibility with rocuronium bromide has been demonstrated or for which compatibility with rocuronium bromide has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.

After dilution with infusion fluids (see section 6.6), chemical and physical in-use stability has been demonstrated for 24 hours at 25°C. 

From a microbiological point of view, the diluted product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user/administrator and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2-8&deg;C).</p><p>Store in the original package in order to protect from light.</p><p><em>Storage out of the refrigerator</em><br />Rucoron can be stored outside of the refrigerator at a temperature of up to 25&deg;C for a maximum of 4 months. The product may be placed in and out the refrigerator at any point(s) during the 36 months shelf life, but the total storage time outside the refrigerator must not exceed 4 months. The storage period may not exceed the labeled shelf life.</p><p>For storage conditions after first opening of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5 ml clear type I glass vials stoppered with rubber stoppers and sealed with aluminum flip-off caps.</p><p>Pack size: 10 Vials (5 ml).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Compatibility studies with the following infusion fluids have been performed: In nominal concentrations of 0.5 mg/ml and 2.0 mg/ml Rucoron has been shown to be compatible with: 0.9% sodium chloride solution, 5% dextrose solution, 5% dextrose in 0.9% sodium chloride solution, water for injection and lactated Ringer&rsquo;s solution. Administration should be begun immediately after mixing, and should be completed within 24 hours. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 June 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>